We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Life Technologies and VelaDx to Develop IVD Tests

By LabMedica International staff writers
Posted on 10 Oct 2012
VelaDx (The Kendall Science Park II, Singapore) signed an agreement with Life Technologies (Carlsbad, CA, USA) to develop and market in vitro diagnostic (IVD) tests on the Ion personal genome machine (PGM) platform. More...
VelaDx will seek approvals from global regulatory authorities for clinical diagnostic tests in oncology and infectious disease.

The Ion PGM System is fast, simple, and flexible, and is complementary to Vela's Sentosa workflow and its menu of quantitative polymerase chain reaction (qPCR) assay kits. Both Ion's PGM and Vela's Sentosa systems can operate on a menu of single tests or multiple panels that can easily be implemented in most laboratories. Data communication with laboratory information systems between the Ion PGM and Sentosa systems will maintain the accuracy of data and improve the efficiency of the laboratory workflow.

The semiconductor sequencing will increase and improve diagnostic tests for personalized medicine. Ion Torrent (Guilford, CA, USA) president and COO, Gregg Fergus explained, "The Ion PGM sequencer uses a novel sequencing technology that directly translates the language of chemistry into the binary language of computers on a semiconductor chip. This new approach has democratized sequencing, making it far more accessible than ever before. The system can perform a sequencing run in just 90 minutes and automated sample prep makes it easy for a lab technician of any experience level to operate. The cost of the Ion PGM system is just a fraction of other systems and accuracy is at a Q30 quality level, both of which are helping to rapidly drive adoption. More than 1,000 units were sold in the system's first 18 months on the market. Life Technologies plans to seek clearance for the Ion PGM System from the FDA as well as approval from other global regulatory agencies."

Target markets addressed by VelaDx are attractive and growing quickly. A recent report by Piper Jaffray, an investment bank and asset management firm, estimated the current infectious disease market to be USD 2 billion annually and growing by more than 8%. United Health Group, a health care company, predicted that the genetic testing market will grow to USD 25 billion by 2021.

Related Links:
VelaDx
Life Technologies
Ion Torrent


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.